Funder: Alnylam Pharmaceuticals
Due Dates: May 29, 2026 (Submission deadline for RFP ALNY-RFP-TTR-13)
Funding Amounts: Up to $250,000 per proposal; multiple proposals may be funded; single or multiple venues/channels possible.
Summary: Supports independent educational initiatives to improve clinical decision-making and patient outcomes in transthyretin-mediated amyloidosis (ATTR-CM).
Key Information: Only accredited organizations may apply; individuals and certain healthcare entities are ineligible.